


## Novaestiq's Partner Croma-Pharma Announces Submission to the U.S. Food and Drug Administration for saypha® MagIQ<sup>™</sup>

1st submission in the United States for saypha® line of dermal fillers represents a key Novaestiq milestone

SOUTHLAKE, TX, UNITED STATES, August 21, 2024 /EINPresswire.com/ --Novaestiq Corp., a growth-oriented aesthetic company that focuses on delivering intelligent and innovative



skin solutions to practices and patients announced today that earlier this year its partner Croma-Pharma GmbH finalized submission of its premarket approval (PMA) application to the U.S. Food and Drug Administration (FDA) for the saypha<sup>®</sup> MagIQ<sup>™</sup> hyaluronic acid dermal filler. Novaestiq plans to commercialize saypha<sup>®</sup> MagIQ<sup>™</sup> beginning in early 2025.

## ٢٢

The submission is a foundational milestone for Novaestiq and supports our effort to create the next great aesthetic company" *Miles Harrison, CEO*  "We are delighted that our partner Croma has submitted this first filler product to the FDA," said Miles Harrison, Chief Executive Officer, Novaestiq. "The submission is a foundational milestone for Novaestiq and supports our effort to create the next great aesthetic company. We look forward to continued collaboration with our partners at Croma as we drive our "Aesthetics for All™" ethos."

The PMA application includes results from the U.S. pivotal study, which evaluated the safety and effectiveness of the products in a multicenter, blinded, split face, controlled, non-inferiority designed trial. Patients were followed for 12 months from initial treatment. A total of 270 patients were enrolled and received saypha<sup>®</sup> MagIQ<sup>™</sup> in one NLF and Juvederm<sup>®</sup> Ultra XC in the contralateral NLF. saypha<sup>®</sup> MagIQ<sup>™</sup> met the primary endpoint at 24 weeks. Additional information will be shared at upcoming medical conferences.

saypha<sup>®</sup> MagIQ<sup>™</sup> has 8+ years of global experience and is manufactured by Croma in Leobendorf, Austria. More than 22 million syringes have been manufactured from the saypha<sup>®</sup> product line demonstrating high quality, a proven safety profile, and consistent performance in

over 80 markets around the world. Novaestiq anticipates that their partner Croma will be submitting a second filler product for approval early in 2025.

## About Novaestiq

Novaestiq is a private, growth-oriented company that boasts a broad range of aesthetic and dermatology products that are both practice and patient/consumer focused. Novaestiq is poised to bring a variety of intelligent and innovative skin solutions to the market in the coming months and years. With a strong emphasis on driving practice success, Novaestiq is set to redefine industry standards. <u>www.novaestiq.com</u>

For media inquiries or further information, please contact:

Drew Fine, Chief Commercial Officer. Email: drew@novaestiq.com

Media Relations Novaestiq Corp. Email: inquiries@novaestiq.com

Drew Fine Novaestiq email us here Visit us on social media: LinkedIn

This press release can be viewed online at: https://www.einpresswire.com/article/736932933

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire<sup>™</sup>, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information. © 1995-2024 Newsmatics Inc. All Right Reserved.